Keeley Teton Advisors LLC Makes New $254,000 Investment in Grail, Inc. (NASDAQ:GRAL)

Keeley Teton Advisors LLC purchased a new stake in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 14,233 shares of the company's stock, valued at approximately $254,000.

Several other institutional investors also recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new position in Grail during the fourth quarter valued at approximately $26,000. Lindbrook Capital LLC purchased a new position in Grail during the fourth quarter valued at approximately $28,000. Sterling Capital Management LLC purchased a new position in Grail during the fourth quarter valued at approximately $29,000. Wellington Shields Capital Management LLC purchased a new stake in shares of Grail in the fourth quarter valued at approximately $33,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Grail in the fourth quarter valued at approximately $59,000.

Grail Stock Up 13.8 %

Shares of Grail stock traded up $4.09 on Wednesday, reaching $33.78. The company's stock had a trading volume of 1,126,249 shares, compared to its average volume of 1,221,425. Grail, Inc. has a 52-week low of $12.33 and a 52-week high of $63.99. The stock has a 50-day moving average price of $32.11 and a 200-day moving average price of $23.85.

Grail (NASDAQ:GRAL - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.41) by $2.55. The business had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million. On average, analysts anticipate that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on GRAL. Canaccord Genuity Group began coverage on Grail in a research report on Monday. They issued a "buy" rating and a $32.00 price objective for the company. Morgan Stanley boosted their price objective on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 18th.

Insider Transactions at Grail

In other news, CFO Aaron Freidin sold 1,816 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the transaction, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at approximately $10,457,304. This trade represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, President Joshua J. Ofman sold 2,109 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total transaction of $65,800.80. Following the completion of the transaction, the president now directly owns 559,673 shares in the company, valued at approximately $17,461,797.60. This represents a 0.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,550 shares of company stock valued at $360,436.

About Grail

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.